Video

Dr. Jae Park on Impact of Disease Burden on CAR T-Cells in Relapsed B-ALL

Author(s):

Jae Park, MD, Hematologic Oncologist, Memorial Sloan Kettering Cancer Center, discusses the impact that disease burden plays on how adult patients with relapsed precursor B acute lymphoblastic leukemia (B-ALL) respond to cd19-targeted CAR modified T-cells.

Heavily pretreated B-ALL patients have demonstrated a remarkable response rate of 80% with cd19-targeted CAR modified T-cells, says Park. Disease burden does not impact how well the CAR-T cells work.

However, the side effects of CAR T- cells do differ depending on disease burden. The more disease a patient has, the more likely they are to experience toxicities, says Park.

The role of a bone marrow transplant for patients that have received CAR-T cells is also being investigated, says Park.

While the results are not definitive, researchers have found that patients with either low or high disease burden who have receive CAR-T cells and achieved a good remission do not appear to benefit form a bone marrow transplant, says Park.

<<<

View more from the 2016 EHA Congress

Related Videos
David C. Fisher, MD
Farrukh Awan, MD
Minoo Battiwalla, MD, MS
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the role of genomic profiling in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the treatment goals in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss factors for picking intensive chemotherapy vs other regimens in acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss dose intensity and sequencing of CPX-351 in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss long-term data for CPX-351 in acute myeloid leukemia.
James K. McCloskey, MD, and Harry P. Erba, MD, PhD, discuss factors to help determine intensive chemotherapy fitness in acute myeloid leukemia.
James K. McCloskey, MD, and Harry P. Erba, MD, PhD, discuss the diagnosis and prevalence of secondary acute myeloid leukemia.